Vol.

No.

October 23, 2020Oct 23, 2020

DOWNLOAD THE PDF

Cover Story

Edward Chu: “The dean and the CEO realized that the cancer center world is evolving.”

Reflections on a dual role as director at Albert Einstein Cancer Center and an executive at the Montefiore Health System

By Paul Goldberg

MSK program opens doors for young cancer researchers from diverse backgrounds

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Rachelle Monteau: I'm a pre-med student because my first exposure to healthcare disparities was through my family

By Matthew Bin Han Ong

COVID-19 & Cancer

Takeaway from the AACI annual meeting: How cancer centers adapted to the COVID-19 pandemic

By Alexandria Carolan

Guest Editorial

Gender equity remains elusive in gyn oncology as women earn less, put up with more

By Sarah M. Temkin and BJ Rimel

Myles Brown, Judy H. Cho, Peter L. Choyke, Yolonda Lorig Colson, Levi A. Garraway, Antoni Ribas, Louis M. Staudt, John E. Dick, among new members of the National Academy of Medicine

Clinical COVID-19 & Cancer Trials & Tribulations

Navigating a pandemic in the nonprofit space: Lessons learned from COVID-19 responses

By Patricia J. Goldsmith

In Brief

Wally Curran steps down as director at Emory Winship

Mark Bonnen named chief medical officer of the Mays Cancer Center

Park named director of hematology and oncology at VICC

Michaela Dinan named co-leader of the Cancer Prevention and Control Research Program at Yale

Rogel team receives $11.2M to leverage the microbiome against GVHD

Yale Cancer Center receives ACGT grant to advance strategies for treating pancreatic cancer

FDA and AACR announce inaugural class of Oncology Educational Fellows

Alliance Cancer Specialists and Northwest Oncology join US Oncology Network

Clinical Roundup

Study: COVID-19 substantially reduced cancer screenings, diagnosis and treatment

ASTRO issues clinical guideline on radiation therapy for rectal cancer

Drugs & Targets

Venclexta combination receives FDA approval for untreated AML

Tagrisso receives FDA Priority Review for adjuvant treatment of early-stage EGFR-mutated lung cancer

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Edward Chu: “The dean and the CEO realized that the cancer center world is evolving.”

MSK program opens doors for young cancer researchers from diverse backgrounds

Rachelle Monteau: I'm a pre-med student because my first exposure to healthcare disparities was through my family

Takeaway from the AACI annual meeting: How cancer centers adapted to the COVID-19 pandemic

Gender equity remains elusive in gyn oncology as women earn less, put up with more

Myles Brown, Judy H. Cho, Peter L. Choyke, Yolonda Lorig Colson, Levi A. Garraway, Antoni Ribas, Louis M. Staudt, John E. Dick, among new members of the National Academy of Medicine

Navigating a pandemic in the nonprofit space: Lessons learned from COVID-19 responses

In Brief

Wally Curran steps down as director at Emory Winship

Mark Bonnen named chief medical officer of the Mays Cancer Center

Park named director of hematology and oncology at VICC

Michaela Dinan named co-leader of the Cancer Prevention and Control Research Program at Yale

Rogel team receives $11.2M to leverage the microbiome against GVHD

Yale Cancer Center receives ACGT grant to advance strategies for treating pancreatic cancer

FDA and AACR announce inaugural class of Oncology Educational Fellows

Alliance Cancer Specialists and Northwest Oncology join US Oncology Network

Clinical Roundup

Study: COVID-19 substantially reduced cancer screenings, diagnosis and treatment

ASTRO issues clinical guideline on radiation therapy for rectal cancer

Drugs & Targets

Venclexta combination receives FDA approval for untreated AML

Tagrisso receives FDA Priority Review for adjuvant treatment of early-stage EGFR-mutated lung cancer

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login